Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 19/20 | 0.81 |
| ▸ | PRKACA | P17612 | 4/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | CIT | O14578 | 1/20 | 0.55 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250252 | 0.90 | ROCK1 (1.00) | ROCK1PRKACAROCK2CYP3A4CIT | |
| SCHEMBL3248699 | 0.88 | ROCK1 (0.85) | ROCK1PRKACAROCK2CYP3A4CIT | |
| SCHEMBL13887726 | 0.86 | ROCK1 (0.77) | ROCK1CYP3A4CITRPS6KA5FLT3 | |
| SCHEMBL3254520 | 0.85 | ROCK1 (1.00) | ROCK1PRKACAROCK2CYP3A4CIT | |
| SCHEMBL3254509 | 0.79 | ROCK1 (0.75) | ROCK1PRKACAROCK2CYP3A4HTT | |
| SCHEMBL5263087 | 0.79 | ROCK1 (0.51) | ROCK1PRKACACYP3A4CITRPS6KA5 | |
| SCHEMBL2766618 | 0.78 | GPR119 (0.58) | ROCK1 | |
| SCHEMBL2768171 | 0.77 | GPR119 (0.60) | — | |
| SCHEMBL3249586 | 0.77 | ROCK1 (1.00) | ROCK1PRKACAROCK2CYP3A4CIT | |
| SCHEMBL6204175 | 0.77 | ROCK1 (0.76) | ROCK1PRKACAROCK2CYP3A4CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558607-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2010-05-05 | — | — | EP | disclosed |
| CN-1732164-A | Compositions useful as inhibitors of ROCK and other protein kinases | VERTEX PHARMA (US) | 2006-02-08 | — | — | CN | disclosed |
| EP-1558607-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040122016-A1 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-24 | — | — | US | disclosed |
| WO-2004041813-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122016-A1 | Compositions useful as inhibitors of rock and other protein kinases | ROCK1, ROCK2, PRKCH | ROCK1 1/4885PRKACA 18/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.